AUS Edition 
NZ Edition 
UK Edition 
CA Edition 
USA Edition 
FRA Edition 
GER Edition 
ESP Edition 
ITA Edition 
NLD Edition 
PRT Edition 
SWE Edition 
GRC Edition 
IND Edition 
POL Edition 
BRA Edition 
ZAF Edition 
RUS Edition 
CHN Edition 
UAE Edition 
⚠
✓
Invitae Corp (NYSE:NVTA)
0.019 USD
-0.011 35.593%Sponsored Reports
Loading...
| Previous Close (in USD) | 0.0295 |
|---|---|
| Change | -0.011 35.593% |
| 52 W H/L (in USD) | 2.940/0.360 |
| EBITDA (in USD) | -353.937M |
| PE Ratio | -- |
| Volume | 22459258 |
| Diluted Eps TTM | -5.36 |
| Total Assets (in USD) | 1954.116M |
|---|---|
| Total Liabilities (in USD) | 1852.28M |
| Revenue TTM (in USD) | 481.583M |
| Cash (in USD) | 257.489M |
| Market Cap (in USD) | 206.476 M |
| Revenue Per Share TTM | 1.864 |
| Gross Profit TTM (in USD) | 99.047M |
Summary
Income Statement
Balance Sheet
Change in Cash
Operating Cash
Invitae Corp
Invitae Corporation, a medical genetics company, that provides genetic information to improve healthcare of people in the United States, Canada, and internationally. The company offers genetic tests in various clinical areas, including hereditary cancer, precision oncology, women's health, rare diseases, and pharmacogenomics; digital health solutions; and health data services. It serves patients, healthcare providers, biopharma companies, and other partners. The company was formerly known as Locus Development, Inc. and changed its name to Invitae Corporation in 2012. Invitae Corporation was incorporated in 2010 and is headquartered in San Francisco, California.
Employees: 1700
Key Executives
| Sr. No. | Name | Title | Year Born |
|---|---|---|---|
| 1. | Mr. Kenneth D. Knight | Pres, CEO & Director | 1961 |
| 2. | Ms. Yafei Wen | Chief Financial Officer | 1973 |
| 3. | Mr. Thomas R. Brida | Gen. Counsel, Chief Compliance Officer & Sec. | 1971 |
| 4. | Dr. Robert L. Nussbaum M.D. | Chief Medical Officer | 1950 |
| 5. | Ms. Shelly D. Guyer | Chief Sustainability Officer | 1960 |
| 6. | Mr. Robert F. Werner | Chief Accounting Officer & Principal Accounting Officer | 1973 |
| 7. | Ms. Hoki Luk | Head of Investor Relations and Capital Markets | 1976 |
| 8. | Mr. Lee Bendekgey J.D. | Chief Policy Officer | 1958 |
| 9. | Glenn Medalle | Head of Talent | NA |
| 10. | Ms. Desarie French | Chief Talent Officer | NA |
Peers
Sector: Healthcare
Industry: Diagnostics & Research
| Company | Change (USD) | Price (USD) | Trailing PE(x) | Forward PE(x) | Price Sales TTM(x) | Price to Book Value(x) | Enterprise Value to Revenue(x) | Enterprise Value to EBITDA(x) |
|
TMO
Thermo Fisher Scientific Inc |
+0.415 0.080% | 519.17 | 34.710 | 23.866 | 4.622 | 4.428 | 5.293 | 20.886 |
|
DHR
Danaher Corporation |
-0.520 0.227% | 230.85 | 29.090 | 28.011 | 5.669 | 3.198 | 5.999 | 19.094 |
|
IDXX
IDEXX Laboratories Inc |
-6.150 1.488% | 417.15 | 49.990 | 45.662 | 11.293 | 27.850 | 11.461 | 34.457 |
|
IQV
IQVIA Holdings Inc |
-2.025 1.031% | 198.82 | 37.820 | 19.685 | 2.764 | 7.195 | 3.607 | 17.031 |
Income Statement
(Currency in USD)| Breakdown | 31-12-2022 | 31-12-2021 | 31-12-2020 | 31-12-2019 | 31-12-2018 |
|---|---|---|---|---|---|
| Income Before Tax | -3151.197M | -415.863M | -714.27M | -260.415M | -132.155M |
| Minority Interest | - | - | - | - | - |
| Net Income | -3106.293M | -379.006M | -608.87M | -241.965M | -129.355M |
| Selling General Administrative | 192.314M | 248.07M | 324.573M | 79.07M | 52.227M |
| Gross Profit | 99.047M | 111.78M | 81.323M | 98.721M | 67.594M |
| Reconciled Depreciation | 142.071M | 80.472M | 39.05M | 16.206M | 13.54M |
| Ebit | -714.236M | -778.287M | -652.172M | -244.112M | -125.125M |
| Ebitda | -564.111M | -672.137M | -645.454M | -231.797M | -111.585M |
| Depreciation And Amortization | 150.125M | 106.15M | 6.718M | 12.315M | 13.54M |
| Operating Income | -714.236M | -778.287M | -652.172M | -244.112M | -122.557M |
| Other Operating Expenses | 1230.539M | 1238.736M | 931.77M | 460.936M | 270.256M |
| Interest Expense | 56.747M | 49.9M | 29.766M | 12.412M | 7.03M |
| Tax Provision | -44.904M | -36.857M | -105.4M | -18.45M | -2.8M |
| Interest Income | - | - | - | 12.412M | 7.03M |
| Net Interest Income | -56.747M | -49.9M | -29.766M | -12.412M | -7.03M |
| Income Tax Expense | -44.904M | -36.857M | -105.4M | -18.45M | -2.8M |
| Total Revenue | 516.303M | 460.449M | 279.598M | 216.824M | 147.699M |
| Total Operating Expenses | 813.283M | 890.067M | 733.495M | 342.833M | 190.151M |
| Cost Of Revenue | 417.256M | 348.669M | 198.275M | 118.103M | 80.105M |
| Total Other Income Expense Net | -2436.961M | 362.424M | -62.098M | -16.303M | -2.568M |
| Net Income From Continuing Ops | -3106.293M | -379.006M | -602.17M | -241.965M | -129.355M |
| Net Income Applicable To Common Shares | -3106.293M | -379.006M | -602.17M | -241.965M | -129.355M |
Balance Sheet
(Currency in USD)| Breakdown | 31-12-2022 | 31-12-2021 | 31-12-2020 | 31-12-2019 | 31-12-2018 |
|---|---|---|---|---|---|
| Total Assets | 1954.116M | 4919.567M | 3423.785M | 781.601M | 282.959M |
| Intangible Assets | 1012.549M | 1187.994M | 981.845M | 125.175M | 30.469M |
| Other Current Assets | 19.496M | 33.691M | 20.2M | 18.032M | 13.258M |
| Total Liab | 1852.28M | 1941.169M | 1454.192M | 401.961M | 121.12M |
| Total Stockholder Equity | 101.836M | 2978.398M | 1969.593M | 379.64M | 161.839M |
| Other Current Liab | 69.574M | 97.022M | 79.68M | 63.385M | 25.802M |
| Common Stock | 0.025M | 0.023M | 0.019M | 0.01M | 0.008M |
| Capital Stock | 0.025M | 0.023M | 0.019M | 0.01M | 0.008M |
| Retained Earnings | -4829.141M | -1722.848M | -1367.547M | -758.677M | -516.712M |
| Good Will | 0M | 2283.059M | 1856.923M | 126.777M | 50.095M |
| Other Assets | -3.858M | 33.826M | 19.874M | 7.264M | 9.07M |
| Cash | 257.489M | 923.25M | 124.794M | 151.389M | 112.158M |
| Cash And Equivalents | - | - | - | - | - |
| Total Current Liabilities | 108.093M | 144.095M | 121.745M | 81.86M | 36.312M |
| Current Deferred Revenue | 4.814M | 9.431M | 6.378M | 1.429M | 0.761M |
| Net Debt | 1493.514M | 800.846M | 325.343M | 167.437M | -34.369M |
| Short Term Debt | 19.721M | 16.515M | 10.484M | 6.725M | 1.937M |
| Short Long Term Debt | - | - | - | - | - |
| Short Long Term Debt Total | 1751.003M | 1724.096M | 450.137M | 318.826M | 77.789M |
| Other Stockholder Equity | 4931.032M | 4701.23M | 3337.12M | 1138.316M | 678.548M |
| Property Plant Equipment | 215.286M | 235.883M | 66.102M | 37.747M | 27.886M |
| Total Current Assets | 693.13M | 1178.805M | 453.932M | 442.398M | 165.439M |
| Long Term Investments | - | - | - | - | 0M |
| Short Term Investments | 289.611M | 122.121M | 229.186M | 240.436M | 13.727M |
| Net Receivables | 96.148M | 66.227M | 47.722M | 32.541M | 26.296M |
| Long Term Debt | 1593.116M | 1577.529M | 388.173M | 268.755M | 74.477M |
| Inventory | 30.386M | 33.516M | 32.03M | 6.6M | 8.3M |
| Accounts Payable | 13.984M | 21.127M | 25.203M | 10.321M | 7.812M |
| Accumulated Other Comprehensive Income | -0.08M | -0.007M | 0.001M | -0.009M | -0.005M |
| Non Currrent Assets Other | 33.151M | 33.826M | 19.874M | 12.864M | 9.07M |
| Non Current Assets Total | 1260.986M | 3740.762M | 2969.853M | 339.203M | 117.52M |
| Capital Lease Obligations | 157.887M | 146.567M | 61.964M | 50.071M | 1.375M |
| Long Term Debt Total | - | 1577.529M | 388.173M | 268.755M | 75.852M |
Cash Flow
(Currency in USD)| Breakdown | 31-12-2022 | 31-12-2021 | 31-12-2020 | 31-12-2019 | 31-12-2018 |
|---|---|---|---|---|---|
| Investments | -174.803M | 99.336M | 10.061M | -226.417M | 42.743M |
| Total Cashflows From Investing Activities | -174.803M | -204.08M | -400.583M | -280.31M | 35.773M |
| Total Cash From Financing Activities | 1.758M | 1565.94M | 673.844M | 464.771M | 157.152M |
| Net Income | -3106.293M | -379.006M | -608.87M | -241.965M | -129.355M |
| Change In Cash | -666.006M | 802.045M | -26.092M | 39.408M | 100.705M |
| Begin Period Cash Flow | 933.525M | 131.48M | 157.572M | 118.164M | 17.459M |
| End Period Cash Flow | 267.519M | 933.525M | 131.48M | 157.572M | 118.164M |
| Total Cash From Operating Activities | -492.961M | -559.815M | -299.354M | -145.053M | -92.22M |
| Depreciation | 142.071M | 80.472M | 39.05M | 16.206M | 13.54M |
| Other Cashflows From Investing Activities | - | -1.3M | -387.779M | -33.846M | -1M |
| Dividends Paid | - | - | - | - | - |
| Change To Inventory | 3.13M | -1.486M | -7.832M | 11.318M | 2.119M |
| Sale Purchase Of Stock | - | 23.767M | 284.203M | 9.47M | 17.511M |
| Other Cashflows From Financing Activities | -10.647M | 1111.669M | 130.953M | 328.352M | 89.3M |
| Capital Expenditures | 53.309M | 54.72M | 22.865M | 20.047M | 5.97M |
| Change In Working Capital | -25.341M | -27.617M | 15.972M | 8.771M | -3.752M |
| Other Non Cash Items | 2342.202M | -376.882M | 201.147M | 14.437M | 9.359M |
| Free Cash Flow | -546.27M | -614.535M | -322.219M | -165.1M | -98.19M |
Funds
| Sr. No. | Name | Purchased On | Shares |
|---|---|---|---|
| 1. | ARK Innovation ETF | 1 year ago | 19344290 |
| 2. | ARK Disruptive Innovation Full Composite | 1 year ago | 18882867 |
| 3. | Nikko AM ARK Disruptive Innovation A USD | 1 year ago | 11253972 |
| 4. | ARK Genomic Revolution ETF | 1 year ago | 9152119 |
| 5. | ARK Genomic Revolution | 1 year ago | 9058622 |
| 6. | Vanguard Total Stock Mkt Idx Inv | 1 year ago | 8208345 |
| 7. | iShares Russell 2000 ETF | 1 year ago | 6326347 |
| 8. | Nikko AM ARK Pstv Chg Innovt P JPY Acc | 1 year ago | 4341307 |
| 9. | Vanguard Institutional Extnd Mkt Idx Tr | 1 year ago | 3688951 |
| 10. | Fidelity® Small Cap Index | 1 year ago | 2422829 |
| 11. | State St Russell Sm/Mid Cp® Indx NL Cl C | 1 year ago | 2348236 |
| 12. | iShares Russell 2000 Growth ETF | 1 year ago | 2051633 |
| 13. | SPDR® S&P Kensho New Economies Comps ETF | 1 year ago | 1796092 |
| 14. | iShares Biotechnology ETF | 1 year ago | 1781310 |
| 15. | JPM Thematics Genetic Thrps C2 Acc USD | 1 year ago | 1496659 |
| 16. | Invesco FTSE RAFI US 1500 Small-Mid ETF | 1 year ago | 1431776 |
| 17. | American Beacon ARK Transfmt Innov R5 | 1 year ago | 1300112 |
| 18. | Schwab US Small-Cap ETF™ | 1 year ago | 1269438 |
| 19. | State St Russell Sm Cap® Indx SL Cl I | 1 year ago | 999939 |
| 20. | iShares Genomics Immnlgy & Hlthcr ETF | 1 year ago | 922930 |
Institutions
| Sr. No. | Name | Purchased On | Shares |
|---|---|---|---|
| 1. | ARK Investment Management LLC | 1 year ago | 32942606 |
| 2. | BlackRock Inc | 1 year ago | 20797979 |
| 3. | Nikko Asset Management Americas Inc | 1 year ago | 16764480 |
| 4. | Sumitomo Mitsui Trust Holdings Inc | 1 year ago | 16764480 |
| 5. | Vanguard Group Inc | 1 year ago | 13527507 |
| 6. | State Street Corporation | 1 year ago | 7958947 |
| 7. | Geode Capital Management, LLC | 1 year ago | 5124199 |
| 8. | Redmile Group, LLC | 1 year ago | 2280403 |
| 9. | Northern Trust Corp | 1 year ago | 2241489 |
| 10. | Charles Schwab Investment Management Inc | 1 year ago | 2103253 |
| 11. | State Treasurer State Of Michigan | 1 year ago | 1959939 |
| 12. | Baker Bros Advisors LP | 1 year ago | 1764546 |
| 13. | JPMorgan Chase & Co | 1 year ago | 1672955 |
| 14. | Mirae Asset Global Investments (Korea) Co Ltd | 1 year ago | 1652650 |
| 15. | Morgan Stanley - Brokerage Accounts | 1 year ago | 1635925 |
| 16. | Goldman Sachs Group Inc | 1 year ago | 1619138 |
| 17. | Susquehanna International Group, LLP | 1 year ago | 1582856 |
| 18. | Amvescap Plc. | 1 year ago | 1505866 |
| 19. | Barclays PLC | 1 year ago | 905531 |
| 20. | Bank of New York Mellon Corp | 1 year ago | 877217 |
Data Powered by EOD Historical Data (“EODHD”). All CFDs (stocks, indices, mutual funds, ETFs), and Forex are not provided by exchanges but rather by market makers, and so prices may not be accurate and may differ from the actual market price, meaning prices are indicative and not appropriate for trading purposes. EODHD is not using exchanges data feeds for the pricing data, EODHD is using OTC, peer to peertrades and trading platforms over 100+ sources, EODHD is aggregating its data feeds via VWAP method. Therefore, EOD Historical Data doesn’t bear any responsibility for any trading losses you might incur as a result of using this data. EOD Historical Data or anyone involved with EOD Historical Data will not accept any liability for loss or damage as a result of reliance on the information including data, quotes, charts and buy/sell signals contained within this website. Please be fully informed regarding the risks and costs associated with trading the financial markets, it is one of the riskiest investment forms possible. EOD Historical Data does not give any warranties (including, without limitation, as to merchantability or fitness for a particular purpose or use).
Related Articles
Loading...
